UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049674 |
|---|---|
| Receipt number | R000056578 |
| Scientific Title | The study to investigate the anti-aging efficacy of intravenous infusion of nicotinamide mononucleotide |
| Date of disclosure of the study information | 2022/12/03 |
| Last modified on | 2022/12/02 17:34:42 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The study to investigate the anti-aging efficacy of intravenous infusion of nicotinamide mononucleotide
Acronym
The study to investigate the anti-aging efficacy of intravenous infusion of NMN
Scientific Title
The study to investigate the anti-aging efficacy of intravenous infusion of nicotinamide mononucleotide
Scientific Title:Acronym
The study to investigate the anti-aging efficacy of intravenous infusion of NMN
Region
| Japan |
Condition
Condition
healthy subjects
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the anti-aging efficacy of intravenous infusion of nicotinamide mononucleotide for healthy individuals
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
To evaluate the skeletal muscle index by the bioelectrical impedence analysis
Key secondary outcomes
To evaluate the parameters related to glucose and lipid metabolism, hormone levels in blood
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
The healthy subjects who agree to study
Key exclusion criteria
1.The subjects with malignant neoplasms.
2.The subjects judged as ineligible by clinical investigators
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | Akane |
| Middle name | |
| Last name | Yu |
Organization
Sense Skin Clinic
Division name
Sense Skin Clinic
Zip code
221-0052
Address
15-2-2F, Sakaecho, Kanagawa-ku, Yokohama, Kanagawa
TEL
0454446022
akanenaka@hotmail.com
Public contact
Name of contact person
| 1st name | Akane |
| Middle name | |
| Last name | Yu |
Organization
Sense Skin Clinic
Division name
Sense Skin Clinic
Zip code
221-0052
Address
15-2-2F, Sakaecho, Kanagawa-ku, Yokohama, Kanagawa
TEL
0454446022
Homepage URL
akanenaka@hotmail.com
Sponsor or person
Institute
Sense Skin Clinic
Institute
Department
Personal name
Funding Source
Organization
Sense Skin Clinic
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Furuta Clinic
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Japanese Organization for Safety Assessment of Clinical Research
Address
13-16 Sanjominami-cho, Ashiya, Hyogo, Japan
Tel
0797-22-5511
info@sacrj.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 12 | Month | 03 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2020 | Year | 09 | Month | 30 | Day |
Date of IRB
| 2022 | Year | 07 | Month | 27 | Day |
Anticipated trial start date
| 2020 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2023 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
To evaluate the parameters related to lipid and glucose metabolism, hormone levels in blood
Management information
Registered date
| 2022 | Year | 12 | Month | 02 | Day |
Last modified on
| 2022 | Year | 12 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056578
